Patricia A Ganz, Hanna Bandos, Charles E Geyer, André Robidoux, Alexander H G Paterson, Jonathan Polikoff, Luis Baez-Diaz, Adam M Brufsky, Louis Fehrenbacher, Ann W Parsons, Patrick J Ward, Louise Provencher, John T Hamm, Philip J Stella, Robert L Carolla, Richard G Margolese, Henry R Shibata, Edith A Perez, Norman Wolmark
BACKGROUND: The NSABP B-36 compared four cycles of doxorubicin and cyclophosphamide (AC) with six cycles of 5-fluorouracil, epirubicin, and cyclophosphamide (FEC-100) in node-negative early-stage breast cancer. A sub-study within B-36, focusing on symptoms, quality of life (QOL), menstrual history (MH), and cardiac function (CF) was conducted. PATIENTS AND METHODS: Patients completed the QOL questionnaire at baseline, during treatment, and every 6 months through 36 months...
February 2022: Breast Cancer Research and Treatment